Business & Finance
BioNTech to expand ongoing trial programme to develop more anti-Omicron COVID-19 variant vaccine options
30 March 2022 -

German biotechnology company BioNTech SE (Nasdaq:BNTX) has said it will expand an ongoing clinical trial programme to develop new vaccines and patterns of administration for better protection against the dominant Omicron COVID-19 variant, Reuters news agency reported on Wednesday.

According to the company, this addition of cohorts to a trial programme initially unveiled in January 2022 comes as global infection numbers are on the rise and protection against infection from its established Comirnaty vaccine, co-developed with Pfizer (NYSE:PFE), has waned.

BioNtech plans to spend between EUR1.4bn to EUR1.5bn on research and development this year, thanks to a EUR10.3bn net income in 2021.

The company also reiterated its 2022 vaccine revenue guidance of between EUR13bn to EUR17bn.



Related Headlines